Jiwon Oh

List of Publications by Year
in descending order

102 papers	4,736 citations	159585 30 h-index	106344 65 g-index
105 all docs	105 docs citations	105 times ranked	6286 citing authors

#	Article	IF	Citations
1	Restoring Systemic GDF11 Levels Reverses Age-Related Dysfunction in Mouse Skeletal Muscle. Science, 2014, 344, 649-652.	12.6	706
2	Multiple sclerosis: clinical aspects. Current Opinion in Neurology, 2018, 31, 752-759.	3.6	324
3	Optical coherence tomography reflects brain atrophy in multiple sclerosis: A four‑year study. Annals of Neurology, 2015, 78, 801-813.	5.3	304
4	2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurology, The, 2021, 20, 653-670.	10.2	302
5	Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis. American Journal of Neuroradiology, 2016, 37, 394-401.	2.4	277
6	The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nature Reviews Neurology, 2016, 12, 714-722.	10.1	274
7	Relationships Between Retinal Axonal and Neuronal Measures and Global Central Nervous System Pathology in Multiple Sclerosis. JAMA Neurology, 2013, 70, 34.	9.0	197
8	DeepHarmony: A deep learning approach to contrast harmonization across scanner changes. Magnetic Resonance Imaging, 2019, 64, 160-170.	1.8	150
9	Association of Cortical Lesion Burden on 7-T Magnetic Resonance Imaging With Cognition and Disability in Multiple Sclerosis. JAMA Neurology, 2015, 72, 1004.	9.0	140
10	The potential of serum neurofilament as biomarker for multiple sclerosis. Brain, 2021, 144, 2954-2963.	7.6	98
11	Volumetric Analysis from a Harmonized Multisite Brain MRI Study of a Single Subject with Multiple Sclerosis. American Journal of Neuroradiology, 2017, 38, 1501-1509.	2.4	95
12	Magnetic susceptibility contrast variations in multiple sclerosis lesions. Journal of Magnetic Resonance Imaging, 2016, 43, 463-473.	3.4	79
13	Spinal cord quantitative MRI discriminates between disability levels in multiple sclerosis. Neurology, 2013, 80, 540-547.	1.1	72
14	Spinal Cord Atrophy in Multiple Sclerosis: A Systematic Review and Meta‑Analysis. Journal of Neuroimaging, 2018, 28, 556-586.	2.0	72
15	Multiparametric MRI correlates of sensorimotor function in the spinal cord in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 427-435.	3.0	68
16	Brain and retinal atrophy in African-Americans versus Caucasian-Americans with multiple sclerosis: a longitudinal study. Brain, 2018, 141, 3115-3129.	7.6	67
17	Neuromyelitis Optica: An Antibody-Mediated Disorder of the Central Nervous System. Neurology Research International, 2012, 2012, 1-13.	1.3	64
18	Automatic magnetic resonance spinal cord segmentation with topology constraints for variable fields of view. NeuroImage, 2013, 83, 1051-1062.	4.2	63

#	Article	IF	Citations
19	Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations. Canadian Journal of Neurological Sciences, 2020, 47, 437-455.	0.5	63
20	Imaging outcome measures of neuroprotection and repair in MS. Neurology, 2019, 92, 519-533.	1.1	53
21	Relationships between quantitative spinal cord MRI and retinal layers in multiple sclerosis. Neurology, 2015, 84, 720-728.	1.1	52
22	Thalamic lesions in multiple sclerosis by 7T MRI: Clinical implications and relationship to cortical pathology. Multiple Sclerosis Journal, 2015, 21, 1139-1150.	3.0	49
23	The Central Vein Sign in Radiologically Isolated Syndrome. American Journal of Neuroradiology, 2019, 40, 776-783.	2.4	41
24	Paramagnetic Rim Sign in Radiologically Isolated Syndrome. JAMA Neurology, 2020, 77, 653.	9.0	40
25	Quantitative spinal cord MRI in radiologically isolated syndrome. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e436.	6.0	39
26	Management strategies for female patients of reproductive potential with multiple sclerosis: An evidence-based review. Multiple Sclerosis and Related Disorders, 2019, 32, 54-63.	2.0	37
27	Spinal Cord Normalization in Multiple Sclerosis. Journal of Neuroimaging, 2014, 24, 577-584.	2.0	35
28	Intensity warping for multisite MRI harmonization. NeuroImage, 2020, 223, 117242.	4.2	34
29	Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects. Therapeutic Advances in Neurological Disorders, 2014, 7, 239-252.	3.5	33
30	Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement. Journal of Neuroimmunology, 2021, 357, 577627.	2.3	33
31	Comparison of Sagittal FSE T2, STIR, and T1-Weighted Phase-Sensitive Inversion Recovery in the Detection of Spinal Cord Lesions in MS at 3T. American Journal of Neuroradiology, 2016, 37, 970-975.	2.4	32
32	Emerging injectable therapies for multiple sclerosis. Lancet Neurology, The, 2013, 12, 1115-1126.	10.2	31
33	Deep grey matter injury in multiple sclerosis: a NAIMS consensus statement. Brain, 2021, 144, 1974-1984.	7.6	31
34	Severe, acute meningeal irritative reaction after epidural blood patch. Anesthesia and Analgesia, 1998, 87, 1139-40.	2.2	30
35	Established disease-modifying treatments in relapsing-remitting multiple sclerosis. Current Opinion in Neurology, 2015, 28, 220-229.	3.6	29
36	An update of teriflunomide for treatment of multiple sclerosis. Therapeutics and Clinical Risk Management, 2013, 9, 177.	2.0	28

#	Article	IF	Citations
37	Gradient nonlinearity effects on upper cervical spinal cord area measurement from 3D T$_1$‐weighted brain MRI acquisitions. Magnetic Resonance in Medicine, 2018, 79, 1595-1601.	3.0	27
38	Multisite reliability and repeatability of an advanced brain MRI protocol. Journal of Magnetic Resonance Imaging, 2019, 50, 878-888.	3.4	27
39	Cognitive impairment, the central vein sign, and paramagnetic rim lesions in RIS. Multiple Sclerosis Journal, 2021, 27, 2199-2208.	3.0	25
40	Emerging therapies to target CNS pathophysiology in multiple sclerosis. Nature Reviews Neurology, 2022, 18, 466-475.	10.1	25
41	An Automated Statistical Technique for Counting Distinct Multiple Sclerosis Lesions. American Journal of Neuroradiology, 2018, 39, 626-633.	2.4	24
42	Imaging Mechanisms of Disease Progression in Multiple Sclerosis: Beyond Brain Atrophy. Journal of Neuroimaging, 2020, 30, 251-266.	2.0	24
43	Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years. Multiple Sclerosis and Related Disorders, 2020, 43, 102146.	2.0	23
44	Central vein sign: A diagnostic biomarker in multiple sclerosis (CAVS-MS) study protocol for a prospective multicenter trial. NeuroImage: Clinical, 2021, 32, 102834.	2.7	23
45	Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis. Neurology, 2014, 82, 984-988.	1.1	22
46	Diagnosis and management of secondary-progressive multiple sclerosis: time for change. Neurodegenerative Disease Management, 2019, 9, 301-317.	2.2	22
47	A Disentangled Latent Space for Cross-Site MRI Harmonization. Lecture Notes in Computer Science, 2020, , 720-729.	1.3	22
48	Safety, Tolerability, and Efficacy of Oral Therapies for Relapsing-Remitting Multiple Sclerosis. CNS Drugs, 2013, 27, 591-609.	5.9	21
49	Manifestations and impact of the COVID‐19 pandemic in neuroinflammatory diseases. Annals of Clinical and Translational Neurology, 2021, 8, 918-928.	3.7	21
50	Canadian Expert Panel Recommendations for MRI Use in MS Diagnosis and Monitoring. Canadian Journal of Neurological Sciences, 2015, 42, 159-167.	0.5	20
51	Head-to-head drug comparisons in multiple sclerosis. Neurology, 2019, 93, 793-809.	1.1	20
52	Progress in MS‐classification, mechanisms and treatment. Nature Reviews Neurology, 2015, 11, 76-78.	10.1	19
53	Comparison of Physician Therapeutic Inertia for Management of Patients With Multiple Sclerosis in Canada, Argentina, Chile, and Spain. JAMA Network Open, 2019, 2, e197093.	5.9	18
54	Implementing the 2017 McDonald criteria for the diagnosis of multiple sclerosis. Nature Reviews Neurology, 2019, 15, 441-445.	10.1	18

#	ARTICLE	IF	CITATIONS
55	Spinal Cord MRI in Multiple Sclerosis. Neurologic Clinics, 2018, 36, 35-57.	1.8	17
56	Challenges in multiple sclerosis care: Results from an international mixed-methods study. Multiple Sclerosis and Related Disorders, 2021, 50, 102854.	2.0	17
57	Therapeutic Inertia in Multiple Sclerosis Care: A Study of Canadian Neurologists. Frontiers in Neurology, 2018, 9, 781.	2.4	16
58	A window into the future? MRI for evaluation of neuromyelitis optica spectrum disorder throughout the disease course. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110143.	3.5	16
59	Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension studyâ˜…â˜…. Multiple Sclerosis and Related Disorders, 2019, 33, 131-138.	2.0	15
60	Teriflunomide for the Treatment of Multiple Sclerosis. Seminars in Neurology, 2013, 33, 045-055.	1.4	14
61	The NAIMS cooperative pilot project: Design, implementation and future directions. Multiple Sclerosis Journal, 2018, 24, 1770-1772.	3.0	12
62	Productivity loss among people with early multiple sclerosis: A Canadian study. Multiple Sclerosis Journal, 2022, 28, 1414-1423.	3.0	12
63	Teriflunomide. Neurology: Clinical Practice, 2013, 3, 254-260.	1.6	11
64	A NOVEL SEARCH BUILDER TO EXPEDITE SEARCH STRATEGIES FOR SYSTEMATIC REVIEWS. International Journal of Technology Assessment in Health Care, 2015, 31, 51-53.	0.5	11
65	Disease-modifying agents in multiple sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 465-501.	1.8	10
66	New imaging approaches for precision diagnosis and disease staging of MS?. Multiple Sclerosis Journal, 2020, 26, 568-575.	3.0	9
67	Effect of an Educational Intervention on Therapeutic Inertia in Neurologists With Expertise in Multiple Sclerosis. JAMA Network Open, 2020, 3, e2022227.	5.9	9
68	Liddle's syndrome: a report in a middle-aged woman. Yonsei Medical Journal, 2000, 41, 276.	2.2	8
69	Progressive Cognitive Decline in a Patient With Isolated Chronic Neurosarcoidosis. Neurologist, 2010, 16, 50-53.	0.7	8
70	Novel and imminently emerging treatments in relapsingâ€"remitting multiple sclerosis. Current Opinion in Neurology, 2015, 28, 230-236.	3.6	7
71	Deep Harmonization of Inconsistent MR Data for Consistent Volume Segmentation. Lecture Notes in Computer Science, 2018, , 20-30.	1.3	7
72	Toward a Shared-Care Model of Relapsing-Remitting Multiple Sclerosis: Role of the Primary Care Practitioner. Canadian Journal of Neurological Sciences, 2018, 45, 304-312.	0.5	7

#	Article	IF	Citations
73	Assessment of Natural Language Processing Methods for Ascertaining the Expanded Disability Status Scale Score From the Electronic Health Records of Patients With Multiple Sclerosis: Algorithm Development and Validation Study. JMIR Medical Informatics, 2022, 10, e25157.	2.6	7
74	Imaging Markers for Monitoring Disease Activity in Multiple Sclerosis. Current Treatment Options in Neurology, 2017, 19, 18.	1.8	6
75	Five-year longitudinal changes in quantitative spinal cord MRI in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 549-558.	3.0	6
76	Clinical and MRI characteristics of multiple sclerosis in patients of Middle Eastern and North African ancestry residing in Ontario, Canada. Multiple Sclerosis Journal, 2021, 27, 1027-1036.	3.0	6
77	Effect of desire for pregnancy on decisions to escalate treatment in multiple sclerosis care: Differences between MS specialists and non-MS specialists. Multiple Sclerosis and Related Disorders, 2022, 57, 103389.	2.0	6
78	In Vivo Demonstration of Homonymous Hemimacular Loss of Retinal Ganglion Cells Due to a Thalamic Lesion Using Optical Coherence Tomography. JAMA Neurology, 2013, 70, 410.	9.0	5
79	Efficacy and Safety of Teriflunomide in Multiple Sclerosis across Age Groups: Analysis from Pooled Pivotal and Real-world Studies. Journal of Central Nervous System Disease, 2021, 13, 117957352110287.	1.9	5
80	The Canadian prospective cohort study to understand progression in multiple sclerosis (CanProCo): rationale, aims, and study design. BMC Neurology, 2021, 21, 418.	1.8	5
81	Clinical characteristics and outcomes of multiple sclerosis patients with COVID-19 in Toronto, Canada. Multiple Sclerosis and Related Disorders, 2022, 58, 103509.	2.0	5
82	PREGNANCY OUTCOMES IN ALEMTUZUMAB-TREATED PATIENTS WITH RRMS. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.63-e1.	1.9	4
83	Clinical pitfall: false-positive aquaporin-4 IgG leading to misdiagnosis of neuromyelitis optica spectrum disorder in patient with spinal arteriovenous fistula. Spinal Cord Series and Cases, 2017, 3, 17030.	0.6	4
84	Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110242.	1.0	4
85	Usability of an Educational Intervention to Overcome Therapeutic Inertia in Multiple Sclerosis Care. Frontiers in Neurology, 2018, 9, 522.	2.4	3
86	Emotional expressions associated with therapeutic inertia in multiple sclerosis care. Multiple Sclerosis and Related Disorders, 2019, 34, 17-28.	2.0	3
87	Vitamin D as disease-modifying therapy for multiple sclerosis?. Expert Review of Clinical Immunology, 2021, 17, 691-693.	3.0	3
88	Ozanimod for the treatment of relapsing forms of multiple sclerosis. Neurodegenerative Disease Management, 2021, 11, 207-220.	2.2	3
89	Factors associated with treatment escalation among MS specialists and general neurologists: Results from an International cojoint study. Multiple Sclerosis and Related Disorders, 2022, 58, 103404.	2.0	3
90	Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summary. Neurodegenerative Disease Management, 2022, 12, 1-7.	2.2	2

#	Article	IF	Citations
91	Multisite MRI reproducibility of lateral ventricular volume using the NAIMS cooperative pilot dataset. Journal of Neuroimaging, 2022, 32, 910-919.	2.0	2
92	Peripartum disease activity in moderately and severely disabled women with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732211049.	1.0	2
93	Response to 'Foix-Alajouanine is another differential diagnosis in longitudinal myelitis thought to be a case of multiple sclerosis or neuromyelitis optica'. Spinal Cord Series and Cases, 2017, 3, 17059.	0.6	1
94	Detection of central vein should be part of MS diagnostic criteria â€" Commentary. Multiple Sclerosis Journal, 2020, 26, 409-410.	3.0	1
95	Teriflunomide for the Treatment of Multiple Sclerosis. Seminars in Neurology, 2013, 33, 307-308.	1.4	0
96	OP0074â€…Ebselen Is A Potential Anti-Osteoporosis Agent by Suppressing Receptor Activator of Nuclear Factor Kappa-B Ligand-Induced Osteoclast Differentiation In Vitro and Lipopolysaccharide-Induced Inflammatory Bone Destruction In Vivo. Annals of the Rheumatic Diseases, 2016, 75, 82.3-83.	0.9	0
97	1127â€…Pregnancy outcomes in alemtuzumab trials and registry design. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A3.1-A3.	1.9	0
98	Mystery Case: Migraine, hearing loss, and blurred vision in a young woman. Neurology, 2020, 95, e2945-e2950.	1.1	0
99	ICU Service Transitions of Care and the Effect on Patient Outcomes. , 2020, , .		0
100	Short-term effects of air pollution on hospital admission for heart failure among older adults: a time-series study. ISEE Conference Abstracts, 2020, 2020, .	0.0	0
101	Indoor and outdoor particulate matter and serum levels of lead and cadmium among Korean housewives: a panel study. ISEE Conference Abstracts, 2020, 2020, .	0.0	0
102	021â€… Determinants of natalizumab-associated PML outcomes. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A20.1-A20.	1.9	0